Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2011

Open Access 01-12-2011 | Methodology

A randomized controlled trial investigation of a non-stimulant in attention deficit hyperactivity disorder (ACTION): Rationale and design

Authors: Tracey W Tsang, Michael R Kohn, Daniel F Hermens, Simon D Clarke, C Richard Clark, Daryl Efron, Noel Cranswick, Chris Lamb, Leanne M Williams

Published in: Trials | Issue 1/2011

Login to get access

Abstract

Background

The ACTION study (Attention deficit hyperactivity disorder Controlled Trial Investigation Of a Non-stimulant) is a multi-center, double-blind, randomized cross-over trial of the non-stimulant medication, Atomoxetine, in children and adolescents with attention deficit hyperactivity disorder (ADHD). The primary aims are to examine the efficacy of atomoxetine for improving cognition and emotional function in ADHD and whether any improvements in these outcomes are more pronounced in participants with comorbid anxiety; and to determine if changes in these outcomes after atomoxetine are more reliable than changes in diagnostic symptoms of ADHD. This manuscript will describe the methodology and rationale for the ACTION study.

Methods

Children and adolescents aged 6 - 17 y with ADHD will be enrolled. Clinical interview and validated scales will be used to confirm diagnosis and screen for exclusion criteria, which include concurrent stimulant use, and comorbid psychiatric or neurological conditions other than anxiety. Three assessment sessions will be conducted over the 13-week study period: Session 1 (Baseline, pre-treatment), Session 2 (six weeks, atomoxetine or placebo), and Session 3 (13 weeks, cross-over after one-week washout period). The standardized touch-screen battery, "IntegNeuro™", will be used to assess cognitive and emotional function. The primary measure of response will be symptom ratings, while quality of life will be a secondary outcome. Logistic regression will be used to determine predictors of treatment response, while repeated measures of analysis will determine any differences in effect of atomoxetine and placebo.

Results

The methodology for the ACTION study has been detailed.

Conclusions

The ACTION study is the first controlled trial to investigate the efficacy of atomoxetine using objective cognitive and emotional function markers, and whether these objective measures predict outcomes with atomoxetine in ADHD with and without comorbid anxiety. First enrollment was in March 2008. The outcomes of this study will be a significant step towards a 'personalized medicine' (and therefore a more efficient) approach to ADHD treatment.

Trial registration

Australian and New Zealand Clinical Trials Registry ACTRN12607000535​471.
Appendix
Available only for authorised users
Literature
1.
Williams LM, Hermens DF, Thein T, Clark CR, Cooper NJ, Clarke SD, Lamb C, Gordon E, Kohn MR: Using brain-based cognitive measures to support clinical decisions in ADHD. Pediatr Neurol. 2010, 42 (2): 118-26. 10.1016/j.pediatrneurol.2009.08.010.CrossRefPubMed
2.
Rappley MD: Clinical practice Attention deficit-hyperactivity disorder. N Engl J Med. 2005, 352 (2): 165-73. 10.1056/NEJMcp032387.CrossRefPubMed
3.
Svanborg P, Thernlund G, Gustafsson PA, Hagglof B, Schacht A, Kadesjo B: Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents. Eur Child Adolesc Psychiatry. 2009, 18 (12): 725-35. 10.1007/s00787-009-0031-x.CrossRefPubMedPubMedCentral
4.
Escobar R, Montoya A, Polavieja P, Cardo E, Artigas J, Hervas A, Fuentes J: Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009, 19 (3): 253-63. 10.1089/cap.2008.0109.CrossRefPubMed
5.
National Institute of Mental Health: Attention deficit hyperactivity disorder (ADHD). 2008
6.
Barry RJ, Clarke AR, Hajos M, McCarthy R, Selikowitz M, Bruggemann JM: Acute atomoxetine effects on the EEG of children with attention-deficit/hyperactivity disorder. Neuropharmacology. 2009, 57 (7-8): 702-7. 10.1016/j.neuropharm.2009.08.003.CrossRefPubMed
7.
Wigal SB: Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs. 2009, 23 (Suppl 1): 21-31. 10.2165/00023210-200923000-00004.CrossRefPubMed
8.
The MTA Cooperative Group: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999, 56 (12): 1073-86. 10.1001/archpsyc.56.12.1073.CrossRef
9.
Geller D, Donnelly C, Lopez F, Rubin R, Newcorn J, Sutton V, Bakken R, Paczkowski M, Kelsey D, Sumner C: Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2007, 46 (9): 1119-27. 10.1097/chi.0b013e3180ca8385.CrossRefPubMed
10.
Hazell P: Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder. Australas Psychiatry. 2004, 12 (4): 369-375.CrossRefPubMed
11.
Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D, Atomoxetine/Methylphenidate Comparative Study Group: Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008, 165 (6): 721-730. 10.1176/appi.ajp.2007.05091676.CrossRefPubMed
12.
Hammerness P, McCarthy K, Mancuso E, Gendron C, Geller D: Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review. Neuropsychiatr Dis Treat. 2009, 5: 215-226.PubMedPubMedCentral
13.
Kratochvil CJ, Milton DR, Vaughan BS, Greenhill LL: Acute atomoxetine treatment of younger and older children with ADHD: A meta-analysis of tolerability and efficacy. Child Adolesc Psychiatry Ment Health. 2008, 15 (2): 25-10.1186/1753-2000-2-25.CrossRef
14.
Garnock-Jones KP, Keating GM: Spotlight on Atomoxetine in Attention-Deficit Hyperactivity Disorder in Children and Adolescents. CNS Drugs. 2010, 24 (1): 85-8. 10.2165/11203670-000000000-00000.CrossRefPubMed
15.
Daughton JM, Kratochvil CJ: Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls. J Am Acad Child Adolesc Psychiatry. 2009, 48 (3): 240-8. 10.1097/CHI.0b013e318197748f.CrossRefPubMed
16.
Michelson D, Allen AJ, Busner J, Casat CD, Dunn D, Kratochvil CJ, Newcorn J, Sallee FR, Sangal RB, Saylor KE, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D: Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002, 159 (11): 1896-901. 10.1176/appi.ajp.159.11.1896.CrossRefPubMed
17.
Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, Alda JA, Gastaminza X, Garcia-Polavieja MJ, Gilaberte I, Escobar R: Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin. 2009, 25 (11): 2745-54.CrossRefPubMed
18.
Wilens TE, Newcorn JH, Kratochvil CJ, Gao H, Thomason CK, Rogers AK, Feldman PD, Levine LR: Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr. 2006, 149 (1): 112-9. 10.1016/j.jpeds.2006.01.052.CrossRefPubMed
19.
Newcorn JH, Sutton VK, Weiss MD, Sumner CR: Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. J Am Acad Child Adolesc Psychiatry. 2009, 48 (5): 511-8. 10.1097/CHI.0b013e31819c55b2.CrossRefPubMed
20.
Ramoz N, Boni C, Downing AM, Close SL, Peters SL, Prokop AM, Allen AJ, Hamon M, Purper-Ouakil D, Gorwood P: A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). Neuropsychopharmacology. 2009, 34 (9): 2135-42. 10.1038/npp.2009.39.CrossRefPubMed
21.
Svanborg P, Thernlund G, Gustafsson PA, Hagglof B, Poole L, Kadesjo B: Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naive Swedish children and adolescents. Eur Child Adolesc Psychiatry. 2009, 18 (4): 240-9. 10.1007/s00787-008-0725-5.CrossRefPubMed
22.
Takahashi M, Takita Y, Yamazaki K, Hayashi T, Ichikawa H, Kambayashi Y, Koeda T, Oki J, Saito K, Takeshita K, Allen AJ: A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009, 19 (4): 341-50. 10.1089/cap.2008.0154.CrossRefPubMed
23.
Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ: Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004, 114 (1): e1-8. 10.1542/peds.114.1.e1.CrossRefPubMed
24.
Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T, The Atomoxetine ADHD Study Group: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-reponse study. Pediatrics. 2001, 108 (5): e83-10.1542/peds.108.5.e83.CrossRefPubMed
25.
Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ: Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002, 63 (12): 1140-7. 10.4088/JCP.v63n1209.CrossRefPubMed
26.
Weiss M, Tannock R, Kratochvil CJ, Dunn D, Velez-Borras J, Thomason CK, Tamura R, Kelsey D, Stevens L, Allen AJ: A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005, 44 (7): 647-55. 10.1097/01.chi.0000163280.47221.c9.CrossRefPubMed
27.
Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF: Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord. 2004, 8 (2): 45-52. 10.1177/108705470400800202.CrossRefPubMed
28.
Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D: Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry. 2005, 44 (3): 240-8. 10.1097/00004583-200503000-00008.CrossRefPubMed
29.
Ghuman JK, Aman MG, Ghuman HS, Reichenbacher T, Gelenberg A, Wright R, Rice S, Fort C: Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009, 19 (2): 155-66. 10.1089/cap.2008.054.CrossRefPubMedPubMedCentral
30.
Gualtieri CT, Johnson LG: Medications do not necessarily normalize cognition in ADHD patients. J Atten Disord. 2008, 11 (4): 459-469. 10.1177/1087054707305314.CrossRefPubMed
31.
Paul RH, Lawrence J, Williams LM, Richard CC, Cooper N, Gordon E: Preliminary validity of "integneuro": a new computerized battery of neurocognitive tests. Int J Neurosci. 2005, 115 (11): 1549-67. 10.1080/00207450590957890.CrossRefPubMed
32.
Clark CR, Paul RH, Williams LM, Arns M, Fallahpour K, Handmer C, Gordon E: Standardized assessment of cognitive functioning during development and aging using an automated touchscreen battery. Arch Clin Neuropsychol. 2006, 21 (5): 449-67. 10.1016/j.acn.2006.06.005.CrossRefPubMed
33.
Vaughan B, Fegert J, Kratochvil CJ: Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother. 2009, 10 (4): 669-76. 10.1517/14656560902762873.CrossRefPubMed
34.
Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL: CDC growth charts for the United States: Methods and development National Center for Health Statistics. Vital Health Stat. 2000, 11 (246):
35.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 1994, Washington, DC: American Psychiatric Association, Fourth
36.
Silverman WK, Saavedra LM, Pina AA: Test-retest reliability of anxiety symptoms and diagnoses with the Anxiety Disorders Interview Schedule for DSM-IV: Child and parent versions. J Am Acad Child Adolesc Psychiatry. 2001, 40 (8): 937-944. 10.1097/00004583-200108000-00016.CrossRefPubMed
37.
Döpfner M, Steinhausen H, Coghill D, Dalsgaard S, Poole L, Ralston SJ, Rothenberger A, ADORE Study Group: Cross-cultural reliability and validity of ADHD assessed by the ADHD Rating Scale in a pan-European study. Eur Child Adolesc Psychiatry. 2006, 15 (suppl 1):
38.
Wood JJ, Piacentini JC, Bergman RL, McCracken J, Varrios V: Concurrent validity of the Anxiety Disorders Section of the Anxiety Disorders Interview Schedule for DSM-IV: Child and parent versions. J Clin Child Psychol. 2002, 31 (3): 335-342.CrossRef
39.
DuPaul GJ: Parent and teacher ratings of ADHD symptoms: psychometric properties in a community-based sample. J Clin Child Psychol. 1991, 20 (3): 245-253. 10.1207/s15374424jccp2003_3.CrossRef
40.
Conners CK: Conners' rating scales - Revised user's manual. 1997, North Tonawanda, NY: Multi-Health Systems Inc
41.
Lovibond SH, Lovibond PF: Manual for the Depression Anxiety Stress Scales. 1995, Sydney: Psychology Foundation, 2
42.
Williams LM, Hermens DF, Palmer D, Kohn M, Clarke S, Keage H, Clark CR, Gordon E: Misinterpreting emotional expressions in attention-deficit/hyperactivity disorder: evidence for a neural marker and stimulant effects. Biol Psychiatry. 2008, 63 (10): 917-26. 10.1016/j.biopsych.2007.11.022.CrossRefPubMed
43.
Brain Resource: WebNeuro Assessment Manual. 2008, Sydney and San Francisco: Brain Resource, 1.1:
44.
Spielberger CD, Gorsuch RL, Lushene RE: State-Trait Anxiety Inventory Manual. 1970, Palo Alto, CA: Consulting Psychologists Press
45.
Spielberger CD: State-Trait Anxiety Inventory for Children Manual. 1973, Palo Alto, CA: Consulting Psychologists Press
46.
Cross RW, Huberty TJ: Factor analysis of the State-Trait Anxiety Inventory for Children with a sample of seventh- and eighth-grade students. J Psychoeduc Assess. 1993, 11 (3): 232-241. 10.1177/073428299301100303.CrossRef
47.
Williams LM, Gatt JM, Hatch A, Palmer DM, Nagy M, Rennie C, Cooper NJ, Morris C, Grieve S, Dobson-Stone C, Schofield P, Clark CR, Gordon E, Arns M, Paul RH: The INTEGRATE model of emotion, thinking and self regulation: an application to the "paradox of aging". J Integr Neurosci. 2008, 7 (3): 367-404. 10.1142/S0219635208001939.CrossRefPubMed
48.
Guy W: ECDEU Assessment Manual for Psychopharmacology, Revised. 1976, Bethesda, MD: U.S. Department of Health, Education and Welfare
49.
Varni JW, Seid M, Kurtin PS: PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001, 39 (8): 800-12. 10.1097/00005650-200108000-00006.CrossRefPubMed
50.
Wehmeier PM, Dittmann RW, Schacht A, Helsberg K, Lehmkuhl G: Morning and evening behavior in children and adolescents treated with atomoxetine once daily for attention-deficit/hyperactivity disorder (ADHD): Findings from two 24-week, open-label studies. Child Adolesc Psychiatry Ment Health. 2009, 3: 5-10.1186/1753-2000-3-5.CrossRefPubMedPubMedCentral
51.
Williams LM, Tsang TW, Clarke S, Kohn M: An 'Integrative Neuroscience' perspective on ADHD: Linking cognition, emotion, brain and genetics measures with implications for clinical support. Expert Rev Neurother. 2010, 10 (10): 1607-1621. 10.1586/ern.10.140.CrossRefPubMed
52.
Chang K, Nayar D, Howe M, Rana M: Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder. J Child Adolesc Psychopharmacol. 2009, 19 (5): 547-51. 10.1089/cap.2009.0030.CrossRefPubMed
53.
Faraone SV, Biederman J, Spencer T, Michelson D, Adler LA, Reimherr F, Seidman L: Atomoxetine and Stroop task performance in adult attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2005, 15 (4): 664-670. 10.1089/cap.2005.15.664.CrossRefPubMed
54.
Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Faraone SV, Seidman L: Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1998, 155: 693-695.CrossRefPubMed
55.
Arnold LE, Aman MG, Cook AM, Witwer AN, Hall KL, Thompson S, Ramadan Y: Atmoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover trial. J Am Acad Child Adolesc Psychiatry. 2006, 45 (10): 1196-205. 10.1097/01.chi.0000231976.28719.2a.CrossRefPubMed
Metadata
Title
A randomized controlled trial investigation of a non-stimulant in attention deficit hyperactivity disorder (ACTION): Rationale and design
Authors
Tracey W Tsang
Michael R Kohn
Daniel F Hermens
Simon D Clarke
C Richard Clark
Daryl Efron
Noel Cranswick
Chris Lamb
Leanne M Williams
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Trials / Issue 1/2011
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1745-6215-12-77

Other articles of this Issue 1/2011

Trials 1/2011 Go to the issue

Study protocol

Early postoperative cognitive dysfunction and postoperative delirium after anaesthesia with various hypnotics: study protocol for a randomised controlled trial - The PINOCCHIO trial

Study protocol

Effects of Study Design and Allocation on participant behaviour - ESDA: study protocol for a randomized controlled trial

Research

Investigator experiences with financial conflicts of interest in clinical trials

Study protocol

Cognitive training plus a comprehensive psychosocial programme (OPUS) versus the comprehensive psychosocial programme alone for patients with first-episode schizophrenia (the NEUROCOM trial): A study protocol for a centrally randomised, observer-blinded multi-centre clinical trial

Study protocol

Randomized placebo-controlled trial on azithromycin to reduce the morbidity of bronchiolitis in Indigenous Australian infants: rationale and protocol

Study protocol

The OPERA trial: protocol for a randomised trial of an exercise intervention for older people in residential and nursing accommodation